Randomized phase III trial of CC-5013 (lenalidomide, NSC-703813) and low dose dexamethasone (LLD) versus bortezomib (PS-341, NSC-681239), lenalidomide and low dose dexamethasone (BLLD) for induction, in patients with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant

eagle-i ID

Resource Type

Properties

1. ClinicalTrials.gov url

   http://www.clinicaltrials.gov/ct2/show/NCT00644228?term=S0777&rank=1

2. Intervention

   Bortezomib

3. Intervention

   Dexamethasone

4. Intervention

   Lenalidomide

5. Additional Topic(s)

   Antineoplastic combined chemotherapy protocols

6. Resource Description

   RATIONALE: It is not yet known whether lenalidomide and dexamethasone is more effective with or without bortezomib in treating multiple myeloma. PURPOSE: This randomized phase III trial is studying giving lenalidomide and dexamethasone together with bortezomib to see how well it works compared to dexamethasone and lenalidomide alone in treating patients with previously untreated multiple myeloma.

7. Contact

   Berenberg, Jeffrey

8. PI

   Berenberg, Jeffrey

9. Topic

   multiple myeloma

10. Study Population

    Males and females age 18 and older with newly diagnosed multiple myeloma (MM).

11. Website(s)

    http://www.cancer.gov/clinicaltrials/search/view?cdrid=590321&version=healthprofessional

12. Funded by

    SWOG

13. Phase

    Phase 3 clinical trial

14. Performed by

    Clinical Protocol & Data Management Shared Resource